Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
SERACARE LIFE SCIENCES INC (SRLS)
|
Add to portfolio |
|
|
|
| Price: |
$3.35
| | Metrics |
| OS: |
20.2
|
M
| |
5
|
% ROE
|
| Market cap: |
$67.7
|
M
| |
11
|
% ROIC
|
|
Net cash:
|
$19.5
|
M
| |
$0.96
|
per share
|
|
EV:
|
$48.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
$2.1
|
M
| |
23.1
|
x EV/EBIT
|
| EPS |
$0.11
| |
30.9
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 | Sep-30-06 | Sep-30-05 | Sep-30-04 |
| Revenues | 43.5 | 50.4 | 44.4 | 49.0 | 47.3 | 49.2 | 50.3 | 28.4 |
| Revenue growth | -13.7% | 13.4% | -9.3% | 3.5% | -3.8% | -2.2% | 76.9% | 22.6% |
| Cost of goods sold | 26.7 | 29.6 | 29.0 | 33.9 | 33.9 | 32.6 | 50.8 | 17.7 |
| Gross profit | 16.7 | 20.8 | 15.4 | 15.0 | 13.4 | 16.6 | -0.5 | 10.7 |
| Gross margin | 38.5% | 41.3% | 34.8% | 30.7% | 28.3% | 33.8% | -1.0% | 37.8% |
| Selling, general and administrative | 12.3 | 12.7 | 13.7 | 16.1 | 14.5 | 13.3 | 12.0 | 5.1 |
| Research and development | 1.3 | 0.8 | 1.1 | 1.8 | 0.6 | 0.5 | 0.4 | |
| EBIT | 2.6 | 6.8 | 0.0 | -2.9 | -1.7 | 2.8 | -12.9 | 5.6 |
| EBIT margin | 6.0% | 13.6% | -0.1% | -5.9% | -3.6% | 5.7% | -25.6% | 19.8% |
| Pre-tax income | 2.6 | 6.7 | -15.3 | -12.3 | -13.0 | -8.9 | -15.2 | 5.4 |
| Income taxes | -0.1 | 0.0 | 0.0 | -0.4 | 0.1 | 0.0 | -0.5 | 1.2 |
| Tax rate | | 0.1% | | 3.0% | | 0.3% | 3.4% | 23.0% |
| Earnings from continuing ops | 2.7 | 6.7 | -15.4 | -12.0 | -13.1 | -8.9 | -14.7 | 4.2 |
| Earnings from discontinued ops | | | | | -0.1 | -15.4 | -6.4 | |
| Net income | 2.7 | 6.7 | -15.4 | -12.0 | -13.2 | -24.3 | -21.1 | 4.2 |
| Net margin | 6.1% | 13.3% | -34.6% | -24.4% | -27.8% | -49.4% | -41.9% | 14.6% |
| |
| Diluted EPS | $0.14 | $0.35 | ($0.83) | ($0.64) | ($0.82) | ($0.63) | ($1.32) | $0.45 |
| Shares outstanding (diluted) | 19.3 | 19.1 | 18.6 | 18.6 | 15.9 | 14.0 | 11.1 | 9.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|